Airship Names Thomas Butta Chief Strategy and Marketing Officer
27.10.2021 16:05:00 EEST | Business Wire | Press release
Airship, the mobile app experience company, today announced Thomas Butta has joined its executive leadership team as Chief Strategy and Marketing Officer, reporting directly to CEO and president Brett Caine.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005300/en/
SaaS branding expert and veteran CMO Thomas Butta joins Airship as Chief Strategy and Marketing Officer (Photo: Business Wire)
Butta brings over two decades of marketing leadership and brand positioning expertise, resulting in billions of dollars of enterprise value created through market leadership, strategic acquisitions and record-breaking IPOs. Prior to joining Airship, Butta was CMO at SignalFx, and before that Sprinklr, where he redefined brand value around software observability and customer experience management respectively, resulting in SignalFx’s acquisition by Splunk and Sprinklr’s subsequent public offering under the ticker symbol, CXM (NASDAQ). Before that, Butta was a consultant in residence for Andreessen Horowitz, where he developed the firm’s points-of-view on market-changing technologies that supported its industry-leading executive briefing program on innovation. His career spans CMO leadership roles at AppNexus, NICE Systems, Parametric Technology Corporation and Red Hat, among others.
“Tom brings an incredible set of experiences and perspectives gleaned from decades of creating category leadership in rapidly-growing markets,” said Brett Caine, CEO and president at Airship. “We couldn’t be happier to welcome Tom to Airship’s executive team and help more of our customers unlock the full potential of mobile app experiences.”
“All of us understand the world around us is changing dramatically. Mobile apps are quickly becoming the preferred destination for brands and their customers as a smart, effective way to create and capture more value. But it’s not necessarily an easy place to get to—from creating elegant app experiences to reaching business performance targets. That’s why Airship exists,” said Thomas Butta, Chief Strategy and Marketing Officer, Airship. “No one knows more, does more, or cares more when it comes to helping brands master mobile app experiences than Airship, and I’m excited to help lead this mission for the company.”
Join Airship today at Elevate 2021, a virtual global forum for marketers, mobile product owners, and developers, where brands like The Allstate Corporation, Chipotle and Shell will share how they’ve adapted and accelerated mobile app strategies to drive exceptional customer experiences and greater competitive differentiation.
About Airship
No one knows more, does more, or cares more when it comes to helping brands master mobile app experiences than Airship. From the beginning of apps, we powered the first commercial messages and then expanded our data-led approach to all re-engagement channels (mobile wallet, SMS, email), app UX experimentation, proactive in-app conversations and now rich in-app experiences that business users can create and adapt on their own — with no ongoing developer support or app update required.
From the trillions of mobile app interactions we’ve powered for thousands of global brands, we’ve been there, and done that, lending our solutions and expertise to help apps become the pinnacle of elegant customer experiences and winning brand loyalty strategies. One could say Airship has one mission: to go where mobile will take your business.
For more information, visit www.airship.com, read our blog or follow us on Twitter, LinkedIn and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005300/en/
Contact information
North America:
Corey Gault
Airship
+1 503-206-9164
corey@airship.com
Kristen Caron
Aircover Communications
+1 978-407-9283
kristen.caron@aircoverpr.com
Europe:
Ana Williams
Airship
+44 (0)20 3405 5160
Ana.Williams@airship.com
UK:
Pauline Delorme
Tyto PR
+44 7531642983
pauline.delorme@tytopr.com
Airship@tytopr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom